Literature DB >> 21222600

FTD and ALS: a tale of two diseases.

R Ferrari1, D Kapogiannis, E D Huey, P Momeni.   

Abstract

The first reports of disorders that in terms of cognitive and behavioral symptoms resemble frontotemporal dementia (FTD) and in terms of motor symptoms resemble amyotrophic lateral sclerosis (ALS) bring us back to the second half of the 1800s. Over the last 150 years, and especially in the last two decades, there has been growing evidence that FTD signs can be seen in patients primarily diagnosed with ALS, implying clinical overlap among these two disorders. In the last decade pathological investigations and genetic screening have contributed tremendously in elucidating the pathology and genetic variability associated with FTD and ALS. To the most important recentdiscoveries belong TAR DNA binding protein [TARDBP or TDP-43] and the fused in sarcoma gene [FUS] and their implication in these disorders.FTD and ALS are the focus of this review which aims to 1. summarize clinical features by describing the diagnostic criteria and specific symptomatology, 2. describe the morphological aspects and related pathology, 3. describe the genetic factors associated with the diseases and 4. summarize the current status of clinical trials and treatment options. A better understanding of the clinical, pathological and genetic features characterizing FTD and ALS will shed light into overlaps among these two disorders and the underpinning mechanisms that contribute to the onset and development. Nevertheless, advancements in the knowledge of the biology of these two disorders will help developing novel and, hopefully, more effective diagnostic and treatment options.

Entities:  

Mesh:

Year:  2011        PMID: 21222600      PMCID: PMC3801195          DOI: 10.2174/156720511795563700

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  253 in total

1.  A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation.

Authors:  M A van Es; F P Diekstra; J H Veldink; F Baas; P R Bourque; H J Schelhaas; E Strengman; E A M Hennekam; D Lindhout; R A Ophoff; L H van den Berg
Journal:  Neurology       Date:  2009-01-20       Impact factor: 9.910

Review 2.  Frontotemporal dementia.

Authors:  Julie S Snowden; David Neary; David M A Mann
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

3.  Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis.

Authors:  John Dunlop; H Beal McIlvain; Yijin She; David S Howland
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

4.  ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis.

Authors:  Matthew J Greenway; Peter M Andersen; Carsten Russ; Sean Ennis; Susan Cashman; Colette Donaghy; Victor Patterson; Robert Swingler; Dairin Kieran; Jochen Prehn; Karen E Morrison; Andrew Green; K Ravi Acharya; Robert H Brown; Orla Hardiman
Journal:  Nat Genet       Date:  2006-02-26       Impact factor: 38.330

5.  Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations.

Authors:  Jennifer L Whitwell; Clifford R Jack; Matthew Baker; Rosa Rademakers; Jennifer Adamson; Bradley F Boeve; David S Knopman; Joseph F Parisi; Ronald C Petersen; Dennis W Dickson; Michael L Hutton; Keith A Josephs
Journal:  Arch Neurol       Date:  2007-03

6.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

Authors:  Antonella Caccamo; Salvatore Oddo; Lana X Tran; Frank M LaFerla
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

7.  Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study.

Authors:  Sonia M Rosso; Laura Donker Kaat; Timo Baks; Marijke Joosse; Inge de Koning; Yolande Pijnenburg; Daniëlle de Jong; Dennis Dooijes; Wouter Kamphorst; Rivka Ravid; Martinus F Niermeijer; Frans Verheij; H P Kremer; Philip Scheltens; Cornelia M van Duijn; Peter Heutink; John C van Swieten
Journal:  Brain       Date:  2003-07-22       Impact factor: 13.501

8.  The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994.

Authors:  D S Knopman; R C Petersen; S D Edland; R H Cha; W A Rocca
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

9.  Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum.

Authors:  Mari Yoshida
Journal:  Neuropathology       Date:  2004-03       Impact factor: 1.906

10.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more
  96 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 2.  Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.

Authors:  Seth A Bennett; Royena Tanaz; Samantha N Cobos; Mariana P Torrente
Journal:  Transl Res       Date:  2018-10-12       Impact factor: 7.012

3.  ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway.

Authors:  Zhiqiang Deng; Junghyun Lim; Qian Wang; Kerry Purtell; Shuai Wu; Gloria M Palomo; Haiyan Tan; Giovanni Manfredi; Yanxiang Zhao; Junmin Peng; Bo Hu; Shi Chen; Zhenyu Yue
Journal:  Autophagy       Date:  2019-07-30       Impact factor: 16.016

Review 4.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 5.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

Review 6.  Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis.

Authors:  Ashley F Curtis; Mario Masellis; Ging-Yuek Robin Hsiung; Rahim Moineddin; Kathy Zhang; Bonnie Au; Geneva Millett; Ian Mackenzie; Ekaterina Rogaeva; Mary C Tierney
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

7.  TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Authors:  Mauro Montalbano; Salome McAllen; Filippa Lo Cascio; Urmi Sengupta; Stephanie Garcia; Nemil Bhatt; Anna Ellsworth; Eric A Heidelman; Omar D Johnson; Samantha Doskocil; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2020-10-14       Impact factor: 5.996

Review 8.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

Review 9.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

Review 10.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.